Roivant Wins Lisraya Approval In Dermatomyositis, Adding A Once-Daily Pill For A Rare Autoimmune Disease

The Food and Drug Administration on Thursday approved Roivant and its subsidiary Priovant's brepocitinib for the treatment of dermatomyositis, a rare autoimmune disease marked by muscle weakness and a painful skin rash.

The medicine will be marketed as Lisraya and is a once-daily pill. Roivant said dermatomyositis affects between 40,000 and 70,000 people in the U.S.

Why the approval matters

The approval adds a new treatment option in a setting where, according to the source report, high doses of steroids and other immune-suppressing drugs are the current standard of care. That gives Roivant an entry into a rare autoimmune market where an oral therapy may stand out simply by offering an alternative to established suppression-based treatment approaches.

For Roivant, the decision is also a straightforward commercial milestone: a subsidiary-developed asset has moved from development into launch with a branded product in a defined rare-disease population.